Business
-
According to Neurelis, the US Patent and Trademark Office (USPTO) has issued a new patent covering Valtoco diazepam nasal spray. The abstract for US Patent No. 11,241,414, titled “Administration of benzodiazepine compositions,” says that it… Read more . . .
-
SK Bioscience announced that it has partnered with nonprofit research organization IAVI on development of an antiviral nasal spray based on a protein developed by David Baker at the University of Washington. The company noted… Read more . . .
-
Receptor Life Sciences said that it has closed a $9.7 million Series A-1 financing and will use the proceeds for clinical development of its RLS103 cannabidiol DPI. RLS103 is based on MannKind Corporation’s Technosphere particle… Read more . . .
-
The Lundquist Institute for Biomedical Innovation has announced that the Bill & Melinda Gates Foundation has awarded a 2-year grant of $471,858 to principal investigator Frans Walther for further development of an aerosolized synthetic lung surfactant… Read more . . .
-
CDMO Lonza has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), the company said. In the announcement of its IPAC-RS membership, Lonza specifically noted its planned participation in discussions related to particle… Read more . . .
-
The Indian Ministry of Science & Technology’s Technology Development Board (TDB) has signed a development and commercialization agreement with Hyderabad-based Sapigen Biologix, committing ₹100 crores to development of a novel intranasal vaccine against COVID-19 and… Read more . . .
-
OxyContin maker Purdue Pharma will provide an additional $11 million to non-profit Harm Reduction Therapeutics (HRT) for continued development of HRT’s HRT001 naloxone nasal spray for the reversal of opioid overdose. The additional funding was… Read more . . .
-
Virpax has announced an expansion of its license agreement with Nanomerics to add worldwide rights to AnQlar nasal spray, an antiviral mucoadhesive polymer derived from chitosan. The original license agreement, which was announced in August… Read more . . .
-
Funds managed by Oaktree Capital Management will provide $100 million in funding to Impel NeuroPharma, with $50 million of that amount in cash up front as part of a royalty agreement on net sales of… Read more . . .
-
A Swiss-German consortium led by Volker Thiel of the Institute of Virology and Immunology and the University of Bern has partnered with Swiss startup RocketVax to develop two live attenuated intranasal vaccine candidates against SARS-CoV-2… Read more . . .
Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden



